Policy Archive · Episode 13

The Case of the Wired Womb

Explore the real-world policies behind this case. Follow proposed and existing policy, potential gaps, and outcomes as they develop.

• Proposed Policy Proposed federal legislation

  Genomic Data Protection Act

  The Genomic Data Protection Act is proposed federal legislation addressing genetic information held by direct-to-consumer genomic testing companies.

  Identifier

  S. 863

  Jurisdiction

  United States (Federal)

  Status

  Proposed federal legislation

  Dates

  S.863 was introduced in the U.S. Senate on March 5, 2025 and referred to the Senate Committee on Commerce, Science, and Transportation. It has not been enacted.

  Latest update

  March 5, 2025

  Update date

  2025-03-05

  What it does: The proposal would give consumers greater control over genomic information and biological samples held by direct-to-consumer genetic testing companies. Among other protections, it would require covered companies to provide mechanisms allowing consumers to access and delete genomic data and request destruction of biological samples. It would also establish notification requirements involving certain corporate transactions and provide for Federal Trade Commission enforcement.

  Potential impact: Millions of people voluntarily provide genetic information to commercial testing services. Once genetic data enters a commercial ecosystem, questions can extend beyond whether the company is permitted to store it. AI creates an additional question: What happens when genetic information collected for one purpose becomes useful for something entirely different? The proposed legislation would strengthen consumer control over genomic information held by covered direct-to-consumer testing companies. It would not, however, establish a comprehensive framework governing every subsequent use of genetic information by AI systems or its use for biological or reproductive design.

  Sources

  • Congress.gov — S.863, Genomic Data Protection Act
• Proposed Policy Proposed federal legislation

  Protecting Families from Fertility Fraud Act of 2026

  This proposed legislation addresses knowing misrepresentation involving the nature or source of DNA used in assisted reproductive technology.

  Identifier

  H.R. 8295

  Jurisdiction

  United States (Federal)

  Status

  Proposed federal legislation

  Dates

  H.R.8295 was introduced in the House on April 15, 2026 and referred to the House Committee on the Judiciary. It has not been enacted.

  Latest update

  April 15, 2026

  Update date

  2026-04-15

  What it does: H.R.8295 would create a federal criminal offense addressing certain abuses involving assisted reproductive technology, including knowingly misrepresenting the nature or source of DNA used in covered reproductive procedures.

  Potential impact: The proposal addresses a real-world version of one issue raised by "Wired Womb": using genetic material in reproduction in a manner the affected person did not authorize or understand. Its reach is considerably narrower than the fictional scenario. The legislation addresses misconduct involving assisted reproductive technology; it does not establish rules for an autonomous AI or robot independently making reproductive decisions or operating an artificial gestation system. Questions involving parental status and custody would also generally implicate state family law rather than the federal policy examined for this episode.

  Sources

  • Congress.gov — H.R.8295, Protecting Families from Fertility Fraud Act of 2026
  • GovInfo — Introduced Bill Text
• Existing Policy Existing federal law

  Genetic Information Nondiscrimination Act of 2008 (GINA)

  Identifier

  Public Law 110-233

  Jurisdiction

  United States (Federal)

  Status

  Existing federal law

  Dates

  GINA enacted May 21, 2008 (Public Law 110-233)

  Latest update

  May 21, 2008

  Update date

  2008-05-21

  What it does: The Genetic Information Nondiscrimination Act (GINA) prohibits certain uses of genetic information in health insurance and employment. GINA therefore provides important protections against genetic discrimination, but it is not a comprehensive genetic-data privacy law governing every company that collects or uses DNA information.

  Potential impact: For emerging AI systems, the important question is therefore not simply: "Is genetic information protected?" It is also: "Who holds the information, why was it collected, and what is that organization permitted to do with it?" Neither GINA nor HIPAA creates a comprehensive federal framework specifically governing every use of consumer genomic data as an input into AI systems.

  Sources

  • GovInfo — Genetic Information Nondiscrimination Act of 2008, Public Law 110-233
• Existing Policy Existing federal law

  Health Insurance Portability and Accountability Act of 1996 (HIPAA)

  Identifier

  Public Law 104-191

  Jurisdiction

  United States (Federal)

  Status

  Existing federal law

  Dates

  HIPAA was enacted August 21, 1996 as Public Law 104-191. The HIPAA Privacy Rule is codified at 45 CFR Part 160 and Part 164 Subparts A and E (HHS), not FDA.

  Latest update

  August 21, 1996

  Update date

  1996-08-21

  What it does: The HIPAA Privacy Rule can protect genetic information when that information constitutes protected health information held by a covered entity or applicable business associate. That distinction matters. Genetic information maintained in the health-care system may receive HIPAA protection, while genetic information provided through other consumer or commercial relationships does not automatically receive the same protection merely because the information concerns a person's health or DNA.

  Potential impact: For emerging AI systems, the important question is therefore not simply: "Is genetic information protected?" It is also: "Who holds the information, why was it collected, and what is that organization permitted to do with it?" Neither GINA nor HIPAA creates a comprehensive federal framework specifically governing every use of consumer genomic data as an input into AI systems.

  Sources

  • HHS — Summary of the HIPAA Privacy Rule
  • HHS — Does the HIPAA Privacy Rule Protect Genetic Information?
  • eCFR — 45 CFR Part 160 (HIPAA administrative requirements)
  • eCFR — 45 CFR Part 164 Subpart E (HIPAA Privacy Rule)
  • GovInfo — Public Law 104-191 (HIPAA)
• Existing Policy Existing federal guidance

  FDA Oversight of Human Genome Editing

  Gene editing is no longer purely theoretical. CRISPR/Cas9 technology is already used in FDA-approved gene therapy, while FDA guidance establishes regulatory expectations for investigational human gene-therapy products incorporating genome editing.

  Identifier

  FDA Guidance

  Jurisdiction

  United States (Federal)

  Status

  Existing federal guidance

  Dates

  April 2026

  Latest update

  April 2026

  Update date

  2026-04-01

  What it does: FDA's January 2024 guidance addresses development of human gene-therapy products involving genome editing, including product design, manufacturing and testing, nonclinical safety assessment, and clinical-trial considerations. FDA has also issued 2026 draft guidance addressing safety assessment of genome editing using next-generation sequencing.

  Potential impact: These frameworks demonstrate that gene editing itself does not exist outside federal oversight. But their focus is primarily on regulated human gene-therapy products and their safety and development—not on a general system of rules governing AI selection or optimization of human genetic characteristics for reproduction. "Wired Womb" therefore raises a different question: how should existing gene-editing safeguards apply if AI becomes increasingly involved in selecting, designing, or directing genetic outcomes?

  Sources

  • FDA — Human Gene Therapy Products Incorporating Human Genome Editing, January 2024
  • FDA — Safety Assessment of Genome Editing in Human Gene Therapy Products Using Next-Generation Sequencing, Draft Guidance, April 2026
• Existing Policy Existing federal regulatory framework

  FDA Oversight and Artificial Womb Technology

  Artificial womb technology is also no longer solely a science-fiction concept, although today's research is far removed from the complete artificial gestation depicted in "Wired Womb". FDA has already examined regulatory considerations for artificial womb technology, including clinical-development safeguards and the use of these systems to support extremely premature infants.

  Identifier

  FDA Medical Device / Clinical Research Framework

  Jurisdiction

  United States (Federal)

  Status

  Existing federal regulatory framework

  Dates

  September 19, 2023

  Latest update

  September 19, 2023

  Update date

  2023-09-19

  What it does: Existing FDA medical-device and clinical-research frameworks can apply to development and testing of artificial womb technologies intended for medical use. FDA's work in this area has focused on systems intended to support extremely premature infants—not autonomous robotic pregnancy or complete replacement of human gestation.

  Potential impact: That distinction is important. Technology designed to help an extremely premature infant continue developing outside the body presents a different set of legal, medical, and ethical questions from technology designed to gestate an embryo or fetus outside a human body from much earlier stages of development. As artificial-womb research progresses, the distinction between neonatal medical support and artificial gestation may become increasingly important for policymakers.

  Sources

  • FDA — Background on Artificial Womb Technology
  • FDA — Pediatric Advisory Committee, Artificial Womb Technology Meeting Materials
• Policy Gap Partial Gap

  Consumer Genetic Data and AI Use

  Jurisdiction

  United States (Federal)

  Status

  Partial Gap

  What it does: Federal law provides some protection for genetic information, but coverage depends heavily on where the information is held and how it is being used. GINA addresses genetic discrimination in specific contexts. HIPAA protects qualifying health information within its covered framework. The proposed Genomic Data Protection Act would give consumers additional control over genomic data held by covered direct-to-consumer testing companies. But these protections do not create a comprehensive federal framework governing how consumer genetic information may subsequently be analyzed, combined, repurposed, or used by AI systems—including for biological or reproductive purposes. That distinction becomes increasingly important as commercial genetic databases and AI become more capable.

  Potential Policy Question

  What federal protections, if any, should govern the use of consumer genetic and genomic information by AI systems when that information is analyzed, combined, repurposed, or used for purposes beyond those originally authorized by the consumer?

  Sources

  • Congress.gov — S.863, Genomic Data Protection Act
  • HHS — Does the HIPAA Privacy Rule Protect Genetic Information?
• Policy Gap Partial Gap

  AI-Directed Genetic Selection and Engineering

  Jurisdiction

  United States (Federal)

  Status

  Partial Gap

  What it does: FDA already regulates human gene-therapy products incorporating genome editing, and federal guidance addresses safety issues surrounding technologies such as CRISPR. Those frameworks provide meaningful oversight of regulated therapeutic products. They do not, however, establish a comprehensive federal framework specifically governing AI systems used to select, combine, optimize, or engineer human genetic characteristics for reproduction outside existing therapeutic and research pathways.

  Potential Policy Question

  What federal safeguards, if any, should apply when AI or automated systems are used to select, optimize, edit, or engineer human genetic characteristics for reproductive purposes?

  Sources

  • FDA — Human Gene Therapy Products Incorporating Human Genome Editing, January 2024
• Policy Gap Partial Gap

  Complete Artificial Gestation

  Jurisdiction

  United States (Federal)

  Status

  Partial Gap

  What it does: FDA has already begun considering artificial womb technology within its existing medical-device and clinical-research authorities. But today's regulatory focus is substantially different from the technology imagined in "Wired Womb". Current FDA work focuses on artificial womb technologies intended to support extremely premature infants. Judge GPT TV's research did not identify a federal framework specifically designed for complete artificial gestation or technological surrogacy outside a human body.

  Potential Policy Question

  What federal regulatory framework, if any, should govern complete artificial gestation—including the distinction between technology designed to support extremely premature infants and technology intended to perform gestation outside a human body?

  Sources

  • FDA — Background on Artificial Womb Technology
• Policy Gap Potential Gap

  Autonomous Reproductive Decisions

  Jurisdiction

  United States (Federal)

  Status

  Potential Gap

  What it does: Judge GPT TV's research did not identify a federal framework specifically determining when an autonomous AI or robotic system may initiate a consequential reproductive process, or what level of human authorization must remain in place. Questions concerning parentage and custody would generally remain matters of state law.

  Potential Policy Question

  What federal requirements, if any, should govern AI or robotic systems capable of initiating consequential biological or reproductive processes—including requirements for human authorization, meaningful human control, informed consent, and system safeguards?

  Sources

  • Congress.gov — H.R.8295, Protecting Families from Fertility Fraud Act of 2026
  • GovInfo — H.R.8295, Introduced Bill Text
• Policy Gap Partial Gap

  Accountability under Existing Frameworks

  Jurisdiction

  United States (Federal)

  Status

  Partial Gap

  What it does: Existing consumer-protection, medical-device, assisted-reproduction, and product-liability frameworks could potentially address parts of a harmful reproductive outcome involving advanced technology. H.R.8295 would also address certain knowing misrepresentations concerning DNA used in assisted reproductive technology if enacted. Judge GPT TV's research did not identify a federal framework specifically determining how responsibility should be allocated among developers, manufacturers, operators, biotechnology providers, and other participants when such a system causes an unauthorized reproductive outcome. Questions concerning parentage and custody would generally remain matters of state law.

  Potential Policy Question

  What federal requirements, if any, should govern accountability when an unauthorized reproductive outcome occurs—including how responsibility should be allocated among developers, manufacturers, operators, biotechnology providers, and other participants?

  Sources

  • Congress.gov — H.R.8295, Protecting Families from Fertility Fraud Act of 2026
  • GovInfo — H.R.8295, Introduced Bill Text